

RECEIVED
CENTRAL FAX CENTER

APR 28 2008

MANDEL & ADRIANO

INTELLECTUAL PROPERTY ATTORNEYS


572 EAST GREEN STREET, SUITE 203
PASADENA, CALIFORNIA 91101
PHONE 626/395-7801
FAX 626/395-0694

FACSIMILE TRANSMISSION

To: Examiner David J. Blanchard, Ph.D.
Title: Primary Examiner
Institution: United States Patent and Trademark Office
Group Art Unit: 1643
U.S. Serial No.: 10/624,884
Facsimile No.: (571) 273-8300
Total No. of pages: 14

From: Sarah B. Adriano
Date: April 28, 2008
Dkt. No.: 30852.13USII

Certificate under 37 C.F.R. §1.8: I hereby certify that this paper and the attachments herewith are being deposited by facsimile with the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 28, 2008.



Renato Marco P. Domingo

This facsimile message is confidential and may contain attorney privileged information intended only for the use of the individual or company named above. If the reader is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by telephone, so that we may arrange for the return of the original message to us. If you do not receive all of the pages, please contact us at any of the numbers provided above.

APR-28-2008 MON 03:58 PM

FAX NO.

P. 02/14
RECEIVED
CENTRAL FAX CENTER
APR 28 2008

DKT. NO.: 30852.13USI1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard Harkins et al.
Serial No.: 10/624,884 **Examiner:** Dr. David J. Blanchard
Filed: July 22, 2003 **Group Art Unit:** 1643
Title: DNA ENCODING A NOVEL RG1 POLYPEPTIDE

572 East Green Street, Suite 203
Pasadena, California 91101
April 28, 2008

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

**COMMUNICATION FORWARDING
REVOCATION AND POWER OF ATTORNEY**

This communication is forwarding a revocation and power of attorney in connection with the subject application. All future correspondence should be directed to the undersigned.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
SaraLynn Mandel
Registration No. 31,853
Attorneys for Applicants
Mandel & Adriano
572 East Green Street, Suite 203
Pasadena, California 91101
(626) 395-7801
Customer No. 26,941

| | |
|---|----------------|
| I hereby certify that this paper is being deposited by facsimile with the Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450. | |
| <i>Renato Marco P. Domingo</i> | <i>4/28/08</i> |
| Renato Marco P. Domingo | Date |

RECEIVED P. 03/14
CENTRAL FAX CENTER
APR 28 2008

DKT NO.: 30852.13US11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard Harkins et al.
U.S. Serial No.: 10/624,884 Examiner: Dr. David J. Blanchard
Filed: July 22, 2003 Group Art Unit: 1643
Title: DNA ENCODING A NOVEL RG1 POLYPEPTIDE

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

REVOCATION AND POWER OF ATTORNEY

Please revoke any existing Powers of Attorney and appoint the following attorneys and/or patent agents to prosecute this application and/or patent and to transact all business in the U.S. Patent and Trademark Office in connection therewith:



Sarah B. Adriano Reg. No. 34,470
SaraLynn Mandel Reg. No. 31,853

Please direct all correspondence in this application to Mandel & Adriano, 572 East Green Street, Suite 203, Pasadena, California 91101.

Respectfully submitted,

Date: April 24, 2008

By: Bayer Schering Pharma Aktiengesellschaft
i. V.
ppa.

 
Dr. Tanja Pintsch Dr. Jürgen Kostrucha
Patents & Licensing

RECEIVED
CENTRAL FAX CENTER

APR 28 2008

DKT. NO.: 30852.13US11

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Richard Harkins et al.
U.S. Serial No.: 10/624,884 Examiner: Dr. David J. Blanchard
Filed: July 22, 2003 Group Art Unit: 1643
Title: DNA ENCODING A NOVEL RG1 POLYPEPTIDE

CERTIFICATE UNDER 37 C.F.R. § 3.73(b)

Bayer Schering Pharma Aktiengesellschaft, a corporation organized and existing under the laws of Germany, having a place of business at 178 Muellerstrasse, Berlin, Germany, D13342, certifies that it is the assignee of the entire right, title and interest in the patent application identified above by virtue of either:

- A. ☒ An assignment from the inventor(s), of the patent application identified above. The assignment was recorded in the Patent and Trademark Office on March 2, 2004, at Reel 014391, Frame 0217 (copy attached as Exhibit 1).
- B. ☐ A chain of title from the inventor(s) of the patent application identified above to the current assignee as shown below:
1. From: To:
The document was recorded in the Patent and Trademark Office at Reel ,
Frame(s) , or for which a copy thereof is attached.
 2. From: To:
The document was recorded in the Patent and Trademark Office at Reel ,
Frame(s) , or for which a copy thereof is attached.
 3. From: To:
The document was recorded in the Patent and Trademark Office at Reel ,
Frame(s) , or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.
- ☒ Copies of assignments or other documents in the chain of title are attached (Exhibit 2). Specifically, Exhibit 2 shows the name change from Schering Aktiengesellschaft to Bayer Schering Pharma Aktiengesellschaft.


The undersigned has reviewed all the documents in the chain of title of the patent application identified above and, to the best of undersigned's knowledge and belief, title is in the assignee identified above.

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date: April 24, 2008

By: Bayer Schering Pharma Aktiengesellschaft
ppa. i. V.


Dr. Tanja Pintsch



Dr. Jürgen Kostrucha
Patents & Licensing

EXHIBIT 1